贲门失弛缓症的全因与特定病因死亡率:一项全国性匹配队列研究
该全国性匹配队列研究纳入瑞典704例新发贲门失弛缓症成人患者及3348名匹配对照,中位随访9.1年。贲门失弛缓症患者全因死亡风险增加42%(aHR 1.42,95%CI 1.21-1.65),主要与癌症、食管癌和呼吸系统疾病死亡风险升高相关,心血管疾病死亡风险未见显著增加。
要点
- 贲门失弛缓症患者全因死亡风险较一般人群增加42%(aHR 1.42,95%CI 1.21-1.65)。
- 食管癌死亡风险显著升高(aHR 23.19,95%CI 3.27-164.55),癌症和呼吸系统疾病死亡风险亦增加。
- 心血管疾病死亡风险未见显著增加(aHR 1.10,95%CI 0.84-1.45)。
核心结论
- 贲门失弛缓症患者较一般人群死亡率增加42%,提示需要长期随访。
研究设计与样本
- 瑞典全国性匹配队列研究,纳入1969-2017年新发贲门失弛缓症成人704例,随访至2021年12月31日。
- 按年龄、性别、出生年份和县匹配一般人群对照最多5例,共3348名参考个体;二次分析以全同胞作为参考个体。
主要发现
- 中位随访9.1年,贲门失弛缓症组死亡270例,参考组死亡1023例(IR 69.4 vs 51.9/1000人年)。
- 全因死亡aHR 1.42(95%CI 1.21-1.65),相当于每6例贲门失弛缓症患者随访10年额外死亡1例。
- 任何癌症死亡IR 17.4 vs 11.8,aHR 1.65(95%CI 1.21-2.23);食管癌死亡IR 2.7 vs 0.2,aHR 23.19(95%CI 3.27-164.55);呼吸系统疾病死亡IR 7.4 vs 3.9,aHR 2.22(95%CI 1.28-3.87)。
- 心血管疾病死亡IR 22.7 vs 19.6,aHR 1.10(95%CI 0.84-1.45),无显著差异。
- 包括同胞比较在内的敏感性分析结果稳健。
临床怎么用
- 作者认为,贲门失弛缓症患者死亡率升高提示需要长期随访。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Achalasia has been linked to increased mortality, but evidence from large population-based cohorts is scarce. We aimed to assess mortality in individuals with achalasia. METHODS: This nationwide cohort study included all adults in Sweden with incident achalasia (n = 704; 1969-2017; follow-up until December 31, 2021) without any other prior esophageal conditions. Achalasia was defined through International Classification of Disease codes in the Swedish National Patient Register in individuals who underwent endoscopic esophageal examination including biopsy as recorded in the histopathology cohort ESPRESSO. Individuals with achalasia were matched by age, sex, birth year, and county to up to 5 reference individuals (n = 3348) from the general population. In a secondary analysis, full siblings were used as secondary reference individuals. Mortality incidence rates (IRs) and multivariable-adjusted hazard ratios (aHRs) with 95% confidence intervals [Cis] for all-cause and cause-specific mortality were calculated using Cox proportional hazards modeling. RESULTS: During a median follow-up of 9.1 years, there were 270 deaths in individuals with achalasia, and 1023 in reference individuals (IR, 69.4 vs 51.9/1000 person-years). This corresponded to a 1.42-fold increased risk of death (95% CI, 1.21-1.65); or 1 extra death per every 6 individuals with achalasia followed for 10 years. Risk increases were seen for death from any cancer (IR, 17.4 vs 11.8; aHR, 1.65; 95% CI, 1.21-2.23), esophageal cancer (IR, 2.7 vs 0.2; aHR, 23.19; 95% CI, 3.27-164.55), and respiratory disease (IR, 7.4 vs 3.9; aHR, 2.22; 95% CI, 1.28-3.87), but not from cardiovascular disease (IR, 22.7 vs 19.6; aHR, 1.10; 95% CI, 0.84-1.45). Results remained robust across sensitivity analyses, including sibling comparisons. CONCLUSIONS: Individuals with achalasia had a 42% increased mortality rate compared with the general population. The elevated mortality risk indicates a need for long-term follow-up.
引用
- Forss A, Hansson MR, Holmberg D, et al. All-cause and Cause-specific Mortality in Achalasia: A Nationwide Matched Cohort Study. Clin Gastroenterol Hepatol. 2025. PMID: 40220848. doi:10.1016/j.cgh.2025.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。